Applies to the following strength(s): 2.5 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Migraine
Use only after a clear diagnosis of migraine has been established
Initial dose: 2.5 mg orally, once
-Provided there has been some response to first dose, a second dose may be administered at least 2 hours later if migraine returns or symptoms recur.
Maximum dose: 7.5 mg in a 24-hour period
-This drug should not be used to treat basilar or hemiplegic migraines because these patients are at a greater risk of stroke.
-The safety of treating an average of more than 4 migraine attacks in a 30 day period has not been established.
Use: For the acute treatment of migraine with or without aura.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
Mild to moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Use with caution as there is a greater potential for adverse events
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Take orally with water or other liquids
-A second dose should be taken no sooner than 2 hours after the first dose
-This drug should be used only where a clear diagnosis of migraine has been established; if a patient does not respond, the diagnosis of migraine should be reconsidered before treating subsequent attacks.
-This drug is not intended to treat cluster headaches, hemiplegic, or basilar migraines or for the prophylactic treatment of migraines.
-Patients with coronary artery disease (CAD) risk factors should have a cardiovascular evaluation performed prior to initiating therapy; for patients who satisfactorily complete a cardiovascular evaluation, consider administering first dose in a medically supervised setting and perform an ECG immediately following administration.
-Medication overuse headaches may present as migraine-like headaches or as a marked increase in migraine frequency; for patients using acute migraine medications (e.g. ergotamine, triptans, opioids) for 10 or more days per month consider withdrawal of the overused drugs and treatment of withdrawal symptoms.
-ECG monitoring should be considered in the interval following the first dose in patients with risk factors for coronary artery disease (CAD) who have satisfactorily completed a cardiovascular evaluation, consider periodic cardiovascular evaluation in intermittent long-term users with cardiovascular risk factors.
-Monitor blood pressure
-Monitor for serotonin syndrome if concomitant use of selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs) are necessary, particularly when starting therapy or with a new or increased dose of a serotonergic medication.
-Patients should be advised to talk with their doctor or pharmacist before taking any new medications or supplements.
-Patients should be aware of the risk of serious cardiovascular side effects and the importance of seeking medical advice promptly if they occur.
-Patients experiencing no relief from a first dose of this medication should be instructed not to take a second dose without first talking to their healthcare provider.
-Patients should be informed of the possibility of developing medication overuse headaches.
-This drug may impair judgment, thinking, or motor skills; have patient avoid driving or operating machinery until adverse effects are determined.
-Advise patient to speak to physician or health care professional if pregnant, intend to become pregnant, or are breastfeeding.
More about frovatriptan
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 37 Reviews – Add your own review/rating
- Drug class: antimigraine agents
Other brands: Frova
- Frovatriptan Succinate (AHFS Monograph)
- Frovatriptan Succinate Tablets (FDA)
- Frovatriptan (Wolters Kluwer)